Eli Lilly and Company
CorpDigest
Eli Lilly and Company
Financial Performance
Last reviewed: June 2026 · By Swet Parvadiya
Revenue
$45.0B
Market Cap
$700.0B
Net Income
$10.6B
Employees
45,000
$9.3 billion spent on research and development in fiscal year 2024 — a number that exceeds Lilly's entire revenue base in 2009. That reinvestment rate, sustained over years, is the financial explanation for tirzepatide's commercial performance. Drugs of this clinical quality don't emerge from modest R&D budgets. Net income reached $10.59 billion in 2024 on $45 billion in revenue, a 23.5% net margin that reflects the pricing power of a drug that genuinely outperforms its competition. The revenue trajectory has been steep: $28.3 billion in 2021, $28.5 billion in 2022, $34.1 billion in 2023, $45 billion in 2024. Each year's jump is larger than the last, driven by tirzepatide's expansion across indications and geographies. The supply shortage controversy in 2023 had a real financial component. Manufacturing capacity for GLP-1 drugs requires specialized equipment and long lead times. Lilly has committed billions in capital expenditure to expand manufacturing — but the gap between demand and supply means some prescription revenue is being left on the table during a period when competitive dynamics are most favorable. The Loxo Oncology acquisition in 2019 cost approximately $8 billion. The oncology pipeline it delivered — including selpercatinib and other targeted therapies — now contributes revenue that diversifies Lilly's earnings away from the GLP-1 concentration risk. Market capitalization of $700 billion prices in continued GLP-1 dominance and successful Phase 3 outcomes for retatrutide. Either of those assumptions failing would reprice the stock significantly.
Revenue Trend Analysis
YoY Change
+31.9%
4-Year CAGR
+16.4%
Peak Year
2024
Trend
Consistent Growth
Eli Lilly and Company has reported revenue across 5 fiscal years, compounding at +16.4% annually over 4 years. The most recent year saw a 31.9% increase versus the prior year. Revenue peaked in 2024 at $45.0B. Out of 4 reported periods, 4 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2024 | $45.0B | $10.6B | +31.9% |
| FY2023 | $34.1B | — | +19.6% |
| FY2022 | $28.5B | — | +0.8% |
| FY2021 | $28.3B | — | +15.5% |
| FY2020 | $24.5B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Eli Lilly and Company's $10.59 billion 2024 net income on $45 billion revenue represents 23.5% net margin reflecting attractive pharmaceutical industry economics with operating margins of approximately 32% across consolidated operations. The financial performance reflects exceptional Mounjaro/Zepbound commercial success supporting substantial revenue growth and operational leverage, continued diabetes franchise leadership, growing oncology and immunology contributions, and various other operational factors. Operating cash flow generation of approximately $8 billion supports continued capital expenditure (substantial manufacturing capacity investment $13+ billion annually supporting various GLP-1 manufacturing capacity expansion), continued dividend payments (current $5.20 annual dividend representing approximately $4.7 billion annual payout supporting income-oriented investors with 10+ year dividend increase streak), modest share buybacks during favorable conditions, continued debt service supporting approximately $33 billion total debt, and various other capital deployment. Future profitability depends on continued operational execution through various competitive dynamics affecting pharmaceutical industry and various GLP-1 category dynamics.
Eli Lilly and Company's substantial $700+ billion market capitalization (representing world's most valuable pharmaceutical company surpassing Johnson & Johnson, Novo Nordisk, plus various other major pharmaceutical competitors) reflects exceptional growth expectations through Mounjaro/Zepbound commercial expansion supporting various GLP-1 category leadership. Strategic premium valuation reflects continued GLP-1 category growth trajectory (industry projections suggest GLP-1 + GIP plus various successor compounds could become largest pharmaceutical category in history with potential $150+ billion annual industry revenue by 2030), Lilly's superior clinical positioning through tirzepatide dual agonist mechanism, pipeline expansion supporting future GLP-1 evolution (orforglipron oral GLP-1, retatrutide triple agonist, various other pipeline candidates), and various other strategic factors. Strategic challenges include continued substantial growth requirements justifying premium valuation, manufacturing capacity execution supporting various supply requirements, competitive responses from Novo Nordisk and various other competitors, eventual generic GLP-1 competition considerations, and various other operational factors affecting future financial performance through ongoing pharmaceutical industry dynamics.
Eli Lilly and Company funds approximately $13+ billion in annual capital expenditure through various capital sources supporting substantial GLP-1 manufacturing capacity expansion plus various other operational investments. Strategic capital deployment supports Indiana manufacturing expansion ($16+ billion cumulative across multiple Indiana sites), North Carolina manufacturing facility ($1+ billion supporting injectable manufacturing), Ireland Limerick facility ($1+ billion supporting API manufacturing), various other manufacturing investments across multiple countries totaling $50+ billion cumulative manufacturing investment through 2030. Capital funding combines continued operating cash flow generation supporting various capital deployment, debt issuance supporting various capital structure flexibility, and various other capital sources. Strategic implications include continued manufacturing capacity expansion supporting various commercial requirements, supply constraint resolution supporting various patient access, and various other operational benefits. Strategic challenges include continued capital requirements supporting various development activities, manufacturing execution requirements supporting various commercial dynamics, and various other operational considerations through ongoing pharmaceutical industry capacity dynamics.
Eli Lilly and Company faces substantial business performance sensitivity to GLP-1 supply constraints affecting Mounjaro/Zepbound commercial dynamics with continued demand substantially exceeding supply across various markets through 2024 with continued manufacturing capacity expansion supporting various supply resolution through 2025+ timeframe. Strategic supply dynamics include continued substantial demand growth across diabetes and obesity treatment categories supporting various commercial benefits, manufacturing scale-up requirements supporting various production expansion, raw material supply considerations affecting various API production, sterile manufacturing capacity supporting various injectable formulation requirements, and various other supply chain considerations. Strategic responses include massive manufacturing capacity investment supporting various production expansion, supplier relationship management supporting various raw material supply, manufacturing operational excellence supporting various production efficiency, and various other operational responses. Future supply dynamics depend on continued manufacturing capacity expansion completion, raw material supply availability, and various other operational factors affecting various commercial dynamics through ongoing pharmaceutical manufacturing industry evolution.